Sule Waidi Folorunso, Sani Enejoh Simon
Department of Biological Sciences, College of Science, Engineering and Technology, Osun State University, Osogbo, PMB 4494 Osun State Nigeria.
Indian J Virol. 2011 Dec;22(2):90-7. doi: 10.1007/s13337-011-0045-0. Epub 2011 Aug 2.
Increase of (≥) 50 CD4(+) T cells/μl in post-commencement of highly active antiretroviral therapy (HAART) is acceptable as indicator of therapeutic success (TS). We therefore hypothesized that median change in CD4 count of the TS and therapeutic failure (TF) groups were comparable after 3 months; and that no associations existed between HAART outcome and adherence to therapy. One hundred Human immunodeficiency virus (HIV) infected antiretroviral (ARV) naive men on lamivudine + stavudine + nevirapine at Federal Medical Centre (FMC), Lokoja, Kogi State, Nigeria were studied. Data of the men were obtained with interviewer-administered questionnaire forms. Their ethylene diamine tetra acetic acid (EDTA)-treated whole blood samples were analysed with Partec CyFlow(®) Counter for pre-HAART and follow-up CD4 counts. Adherence to the ARV regimen was recorded for each patient as self-reported. We used Mann-Whitney U test, Kruskal-Wallis, Wilcoxon's matched pair and CHI(2) statistical tests for analyses. Overall adherence rate was 95.0%. Though the median follow-up CD4 count was higher (P = 0.001) than the pre-HAART value; only 85% of the men attained TS (increase of ≥50 cells/μl) at follow-up. Median change in CD4 count (+104.0 cells/μl; n = 85) of the TS was higher (P = 0.001) than that (-8.0 cells/μl; n = 15) of TF group; the two groups were however, comparable in age (P = 0.17) and body weight (P = 0.96). Only adherence and pre-HAART CD4 counts were associated (P = 0.001) with HAART outcome; while only age apparently influenced (P = 0.01) adherence rate. Eighty-five percent of the men benefited from the HAART. The success was apparently due to adherence and less than or (≤) 200 pre-HAART CD4 counts; while age ≥40 years appearently reduced adherence level.
在高效抗逆转录病毒治疗（HAART）开始后，CD4(+)T细胞增加（≥）50个/μl可作为治疗成功（TS）的指标。因此，我们假设治疗成功组和治疗失败（TF）组的CD4计数在3个月后的中位数变化具有可比性；并且HAART结果与治疗依从性之间不存在关联。对尼日利亚科吉州洛科贾联邦医疗中心100名初治的感染人类免疫缺陷病毒（HIV）且接受拉米夫定+司他夫定+奈韦拉平治疗的男性进行了研究。通过访员管理的问卷形式获取这些男性的数据。使用帕泰克CyFlow(®)计数器对他们经乙二胺四乙酸（EDTA）处理的全血样本进行分析，以测定HAART治疗前和随访时的CD4计数。每位患者的抗逆转录病毒治疗方案依从性通过自我报告进行记录。我们使用曼-惠特尼U检验、克鲁斯卡尔-沃利斯检验、威尔科克森配对检验和卡方统计检验进行分析。总体依从率为95.0%。尽管随访时CD4计数的中位数高于HAART治疗前的值（P = 0.001）；但随访时只有85%的男性达到治疗成功（增加≥50个细胞/μl）。治疗成功组CD4计数的中位数变化（+104.0个细胞/μl；n = 85）高于治疗失败组（-8.0个细胞/μl；n = 15）（P = 0.
